An observational study in Infertility, Male, sponsored by CRG UZ Brussel. Completed at 1 site in Belgium. Open to participants aged 18 Years to 43 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-06.
Sponsored by CRG UZ Brussel · Observational
This clinical study has been organised to investigate whether microfluidic technology may be considered as a new procedure for routine sperm preparation during assisted reproduction. This is a technique that is already used in other centres.
The Microfluidic Sperm Sorting (MSS) technology reduces the time of sample preparation while selects a sperm population with better motility and less DNA fragmentation as compared to routine procedures. This med-ical device is already CE marked.
Having the intention to implement this technology in our department, we conduct this study to investigate whether the use of MSS has at least the same impact, if not better, on fertilization and embryo quality as compared to standard sperm selection procedures.
To perform ICSI, the best spermatozoa are selected based on their motility. This is done using a standard procedure which is time-consuming and involves centrifugation steps known to induce sperm DNA damage. Just before ICSI, the selection of the sperm cell that will be injected into the egg is based on morphological assessment (at 400x inverted phase contrast microscopy). However, the spermatozoa with DNA damage cannot be identified using microscopic procedures and therefore cannot be excluded for ICSI. It was reported that the sperm cells with DNA damage have a negative impact on embryo development and are correlated with increased miscarriage rate.
A more "close to nature" approach is now available due to the microfluidic sperm sorting (MSS) technology that is using FERTILE series devices (FERTILE and FERTILE PLUS, Koek EU, GmbH). The method is based on the principle of natural sperm selection in a passage through micro-barriers imitating natural environment of female reproductive system (fallopian tubes).
This chemical-free technology does not require any pretreatment of the semen sample, while the sorted sperm shows high motility and low levels of DNA damage. At the day of pick up, the husband provides the semen sample. The sample obtained will be divided in 2 fractions: one fraction will be subject to Microfluidic technology (fraction 1) and the other fraction will represent the control (conventionally prepared sperm; fraction 2).
This device was tested in our laboratory on diagnostic semen samples and proved to select the best sperm population when compared to the standard method.
Due to the encouraging results, we intend to apply microfluidic as the routine procedure for sperm preparation in our department. This procedure will increase the chance of using sperm cells without DNA damage during ICSI and therefore we expect better embryological outcome.
This clinical study has been organised to determine if the embryo quality on day 5 will be similar or better when using microfluidic technology compared to standard procedure.
At the moment of ICSI, half of the eggs of good quality (mature) will be inseminated with sperm from fraction 1 and the other half with sperm from fraction 2. The decision of which fraction will be used to inject the first half of the oocytes is random and is based on a list generated by the computer.
The retrieved oocytes will follow the normal lab procedure after injection: the embryos available on day 3 or day 5/6 that meet our criteria for transfer or cryopreservation will be used for transfer or cryopreservation, no matter from which fraction the sperm was used.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 1,038 is above the median of 200 across 714 observational studies indexed under Infertility.
Browse Infertility studies →CRG UZ Brussel is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Couples undergoing ICSI procedure in CRG UZ Brussel will be included in the trial if they fulfil the inclusion criteria listed.
Exclusion Criteria:
Embryo quality
Compare the embryo quality (Gardner score - Scale blastocyst 1-6 where 6 is best; Inner cell mass A-D where A is best; Throphectoderm A-C where A is best) on day 5 between the two groups.
Time frame: 2 years
Fertilization rate
Compare the fertilization rate (number of fertilized oocytes per number of injected oocytes) between the two groups.
Time frame: 2 years
Embryo morphokinetic parameters
Compare the embryo morphokinetic parameters from day 0 until day 6 recorded via embryoscope Plus (Vitrolife sa) between the two group.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CRG UZ Brussel